US6652882B1
(en)
*
|
1997-10-06 |
2003-11-25 |
Intellipharmaceutics Corp |
Controlled release formulation containing bupropion
|
US6221917B1
(en)
|
1997-12-30 |
2001-04-24 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
US5968553A
(en)
*
|
1997-12-30 |
1999-10-19 |
American Home Products Corporation |
Pharmaceutical composition containing bupropion hydrochloride and an inorganic acid stabilizer
|
US7098206B2
(en)
*
|
1998-01-21 |
2006-08-29 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6998400B2
(en)
|
1998-01-22 |
2006-02-14 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
CA2318960A1
(en)
*
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (+)-bupropion
|
WO1999038504A1
(en)
|
1998-01-29 |
1999-08-05 |
Sepracor Inc. |
Pharmaceutical uses of optically pure (-)-bupropion
|
EP1051164A1
(en)
|
1998-01-29 |
2000-11-15 |
Sepracor, Inc. |
Pharmacological uses of pure (+) -bupropion
|
US6153223A
(en)
*
|
1998-06-05 |
2000-11-28 |
Watson Pharmaceuticals, Inc. |
Stabilized pharmaceutical compositions
|
CN1331576A
(zh)
*
|
1998-06-29 |
2002-01-16 |
药品应用协会有限公司 |
用于缓解疼痛的方法和经皮组合物
|
US6238697B1
(en)
*
|
1998-12-21 |
2001-05-29 |
Pharmalogix, Inc. |
Methods and formulations for making bupropion hydrochloride tablets using direct compression
|
US6734213B2
(en)
|
1999-01-20 |
2004-05-11 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US6855820B2
(en)
*
|
1999-01-20 |
2005-02-15 |
Smithkline Beecham Corporation |
Pharmaceutically active morpholinol
|
US8545880B2
(en)
*
|
1999-02-26 |
2013-10-01 |
Andrx Pharmaceuticals, Llc |
Controlled release oral dosage form
|
US6210716B1
(en)
|
1999-02-26 |
2001-04-03 |
Andrx Pharmaceuticals, Inc. |
Controlled release bupropion formulation
|
US6342496B1
(en)
*
|
1999-03-01 |
2002-01-29 |
Sepracor Inc. |
Bupropion metabolites and methods of use
|
US6337328B1
(en)
*
|
1999-03-01 |
2002-01-08 |
Sepracor, Inc. |
Bupropion metabolites and methods of use
|
US6312716B1
(en)
*
|
1999-05-10 |
2001-11-06 |
Peierce Management Llc |
Patch and method for transdermal delivery of bupropion base
|
US6280763B1
(en)
|
1999-05-10 |
2001-08-28 |
Pierce Management, Llc |
Apparatus and method for transdermal delivery of bupropion
|
CA2406383A1
(en)
*
|
2000-04-13 |
2001-10-25 |
Mayo Foundation For Medical Education And Research |
A.beta.42 lowering agents
|
US6306436B1
(en)
|
2000-04-28 |
2001-10-23 |
Teva Pharmaceuticals Usa, Inc. |
Stabilized, acid-free formulation for sustained release of bupropion hydrochloride
|
US6333332B1
(en)
*
|
2000-08-25 |
2001-12-25 |
Impax Laboratories, Inc. |
Stabilized pharmaceutical compositions containing bupropion hydrochloride
|
US20030044462A1
(en)
*
|
2001-08-20 |
2003-03-06 |
Kali Laboratories, Inc. |
Sustained release tablets containing bupropion hydrochloride
|
AU2003217676B2
(en)
|
2002-02-22 |
2009-06-11 |
Takeda Pharmaceutical Company Limited |
Active agent delivery systems and methods for protecting and administering active agents
|
AU2003231788B2
(en)
|
2002-05-17 |
2008-09-11 |
Duke University |
Method for treating obesity
|
US20050215552A1
(en)
*
|
2002-05-17 |
2005-09-29 |
Gadde Kishore M |
Method for treating obesity
|
US6893660B2
(en)
*
|
2002-11-21 |
2005-05-17 |
Andrx Pharmaceuticals, Inc. |
Stable pharmaceutical compositions without a stabilizer
|
EP1603548A4
(en)
*
|
2003-02-05 |
2007-10-10 |
Myriad Genetics Inc |
COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
|
US20040191298A1
(en)
*
|
2003-03-26 |
2004-09-30 |
Fredrik Nicklasson |
New formulations and use thereof
|
WO2004096201A1
(en)
*
|
2003-04-29 |
2004-11-11 |
Orexigen Therapeutics, Inc. |
Compositions for affecting weight loss
|
US20050042284A1
(en)
*
|
2003-07-11 |
2005-02-24 |
Myriad Genetics, Incorporated |
Pharmaceutical methods, dosing regimes and dosage forms for the treatment of Alzheimer's disease
|
US20050096311A1
(en)
*
|
2003-10-30 |
2005-05-05 |
Cns Response |
Compositions and methods for treatment of nervous system disorders
|
US20060160750A1
(en)
*
|
2004-01-13 |
2006-07-20 |
Krishnan K R R |
Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
|
US7713959B2
(en)
*
|
2004-01-13 |
2010-05-11 |
Duke University |
Compositions of an anticonvulsant and mirtazapine to prevent weight gain
|
KR20060128995A
(ko)
|
2004-01-13 |
2006-12-14 |
듀크 유니버시티 |
체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
|
WO2006001877A2
(en)
*
|
2004-04-13 |
2006-01-05 |
Myriad Genetics, Inc. |
Combination treatment for neurodegenerative disorders comprising r-flurbiprofen
|
US20060100205A1
(en)
*
|
2004-04-21 |
2006-05-11 |
Eckard Weber |
Compositions for affecting weight loss
|
CN1946906A
(zh)
*
|
2004-04-29 |
2007-04-11 |
吉斯通护岸系统股份有限公司 |
用于墙、护墙和类似物的饰面
|
CA2618985A1
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020850A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
WO2006020852A2
(en)
*
|
2004-08-11 |
2006-02-23 |
Myriad Genetics, Inc. |
Pharmaceutical composition and method for treating neurodegenerative disorders
|
US20060099262A1
(en)
*
|
2004-11-08 |
2006-05-11 |
Biokey, Inc. |
Methods and formulations for making controlled release oral dosage form
|
US8586085B2
(en)
*
|
2004-11-08 |
2013-11-19 |
Biokey, Inc. |
Methods and formulations for making pharmaceutical compositions containing bupropion
|
KR100670798B1
(ko)
|
2004-12-17 |
2007-01-17 |
한국전자통신연구원 |
데이터베이스 캐시 시스템
|
US20060204571A1
(en)
*
|
2005-03-12 |
2006-09-14 |
Sun Pharmaceutical Industries Limited |
Stable compositions of bupropion or its pharmaceutically acceptable salts
|
EP2502621A1
(en)
*
|
2005-06-27 |
2012-09-26 |
Valeant International (Barbados) SRL |
Crystalline forms of bupropion HBr
|
CA2615063A1
(en)
*
|
2005-07-22 |
2007-02-01 |
Myriad Genetics, Inc. |
High drug load formulations and dosage forms
|
EA200801080A1
(ru)
*
|
2005-10-14 |
2009-02-27 |
Х. Лундбекк А/С |
Стабильные фармацевтические лекарственные формы, содержащие эсциталопрам и бупропион
|
CA2625835A1
(en)
*
|
2005-10-14 |
2007-05-10 |
Forest Laboratories, Inc. |
Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
|
EP2135603B1
(en)
|
2005-11-22 |
2013-01-02 |
Orexigen Therapeutics, Inc. |
Compositions and methods for increasing insulin sensitivity
|
ES2383330T3
(es)
*
|
2005-11-28 |
2012-06-20 |
Orexigen Therapeutics, Inc. |
Formulación de liberación sostenida de zonisamida
|
AU2007220039A1
(en)
*
|
2006-02-27 |
2007-09-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Inhibitors of the unfolded protein response and methods for their use
|
US8916195B2
(en)
|
2006-06-05 |
2014-12-23 |
Orexigen Therapeutics, Inc. |
Sustained release formulation of naltrexone
|
EP2029135A4
(en)
|
2006-06-13 |
2011-08-17 |
Univ Leland Stanford Junior |
EPOXY HEMMER OF CYSTONE PROTEASES
|
EP2046119A2
(en)
*
|
2006-07-07 |
2009-04-15 |
Myriad Genetics, Inc. |
Treatment of psychiatric disorders
|
US7674479B2
(en)
*
|
2006-07-25 |
2010-03-09 |
Intelgenx Corp. |
Sustained-release bupropion and bupropion/mecamylamine tablets
|
US8703191B2
(en)
|
2006-07-25 |
2014-04-22 |
Intelgenx Corp. |
Controlled-release pharmaceutical tablets
|
KR100843021B1
(ko)
*
|
2006-09-11 |
2008-07-01 |
주식회사 드림파마 |
안정성이 개선된 디에틸프로피온 하이드로클로라이드를포함하는 경구투여용 고형 제제
|
TWI609702B
(zh)
|
2006-11-09 |
2018-01-01 |
歐瑞根治療有限公司 |
層狀醫藥調配物
|
KR20180066272A
(ko)
|
2006-11-09 |
2018-06-18 |
오렉시젠 세러퓨틱스 인크. |
단위 용량 팩키지
|
EP2142183A2
(en)
|
2007-04-09 |
2010-01-13 |
Sepracor Inc. |
Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
|
US9339500B2
(en)
*
|
2008-03-04 |
2016-05-17 |
Intra-Cellular Therapies, Inc. |
Methods of treating vasomotor symptoms
|
MX2010012909A
(es)
*
|
2008-05-30 |
2011-02-25 |
Orexigen Therapeutics Inc |
Metodos para tratamiento de condiciones de grasa visceral.
|
TW201039815A
(en)
|
2009-04-13 |
2010-11-16 |
Resolvyx Pharmaceuticals Inc |
Compositions and methods for the treatment of inflammation
|
US20110136815A1
(en)
|
2009-12-08 |
2011-06-09 |
Horst Zerbe |
Solid oral film dosage forms and methods for making same
|
US10610528B2
(en)
|
2009-12-08 |
2020-04-07 |
Intelgenx Corp. |
Solid oral film dosage forms and methods for making same
|
RU2616496C2
(ru)
|
2010-01-11 |
2017-04-17 |
Ориксиджен Терапьютикс, Инк. |
Способы проведения терапии потери веса у пациентов с доминирующей депрессией (варианты)
|
JP2013539786A
(ja)
|
2010-10-11 |
2013-10-28 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
置換ベンズアミドおよびその使用法
|
KR101534606B1
(ko)
*
|
2011-11-08 |
2015-07-10 |
알보젠코리아 주식회사 |
사포그릴레이트의 안정화된 지속 방출 제제
|
BR112014012129A8
(pt)
|
2011-11-21 |
2017-06-20 |
Calithera Biosciences Inc |
inibidores heterocíclicos de glutaminase
|
CA2873701A1
(en)
|
2012-04-12 |
2013-10-17 |
Auckland Uniservices Limited |
Substituted benzamides and their uses
|
WO2013184837A1
(en)
|
2012-06-06 |
2013-12-12 |
Orexigen Therapeutics, Inc. |
Methods of treating overweight and obesity
|
KR102220175B1
(ko)
|
2012-11-16 |
2021-02-24 |
칼리테라 바이오사이언시즈, 인코포레이티드 |
헤테로사이클릭 글루타미나아제 억제제
|
CN105431546A
(zh)
|
2013-03-15 |
2016-03-23 |
里兰斯坦福初级大学理事会 |
基于活性的探针化合物、组合物及其使用方法
|
US11324670B2
(en)
*
|
2013-10-16 |
2022-05-10 |
Bilal Walk |
Cocoa butter powdered moisturizer
|
US11969421B2
(en)
|
2013-11-05 |
2024-04-30 |
Antecip Bioventures Ii Llc |
Bupropion as a modulator of drug activity
|
BR112016029041A8
(pt)
|
2014-06-13 |
2021-07-20 |
Calithera Biosciences Inc |
uso de um inibidor de glutaminase, composição farmacêutica e kit farmacêutico
|
US10316030B2
(en)
|
2014-08-07 |
2019-06-11 |
Calithera Biosciences, Inc. |
Crystal forms of glutaminase inhibitors
|
ES2901418T3
(es)
|
2014-08-13 |
2022-03-22 |
Eolas Therapeutics Inc |
Difluoropirrolidinas como moduladores del receptor de orexina
|
EP3212195A4
(en)
|
2014-10-31 |
2018-06-06 |
The Regents of The University of California |
Compositions and methods for treating hiv-associated cognitive dysfunction
|
KR101612197B1
(ko)
*
|
2014-11-25 |
2016-04-14 |
알보젠코리아 주식회사 |
부프로피온 염산염을 함유하는 안정화된 정제 및 이의 제조방법
|
EA034708B1
(ru)
|
2015-03-10 |
2020-03-10 |
Ауриджен Дискавери Текнолоджис Лимитед |
1,2,4-оксадиазольные и тиадиазольные соединения в качестве иммуномодуляторов
|
US10143699B2
(en)
|
2015-06-23 |
2018-12-04 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
GB2542881B
(en)
|
2015-10-02 |
2020-01-01 |
Carr Andrew |
Crystal forms of ß-nicotinamide mononucleotide
|
WO2017062354A1
(en)
|
2015-10-05 |
2017-04-13 |
Calithera Biosciences, Inc. |
Combination therapy with glutaminase inhibitors and immuno-oncology agents
|
EP3368541B1
(en)
|
2015-10-30 |
2020-05-27 |
Calithera Biosciences, Inc. |
Compositions and methods for inhibiting arginase activity
|
AU2016355429B2
(en)
|
2015-11-16 |
2021-05-06 |
Cerecor, Inc. |
Nucleic acid prodrugs
|
PT3414241T
(pt)
|
2016-02-12 |
2022-07-29 |
Astrazeneca Ab |
Piperidinas substituídas por halo como moduladores de recetores de oxerina
|
WO2017210565A1
(en)
|
2016-06-03 |
2017-12-07 |
Prisident And Fellows Of Harvard College |
Antifungal compounds
|
WO2018039612A1
(en)
|
2016-08-26 |
2018-03-01 |
The Regents Of The University Of California |
Compositions and methods for promoting hair growth with mpc1 inhibitors
|
EP3509583B1
(en)
|
2016-09-09 |
2021-06-30 |
The Regents of the University of California |
Estrogen receptor ligands, compositions and methods related thereto
|
CN110234656B
(zh)
|
2016-09-09 |
2023-02-28 |
卡利泰拉生物科技公司 |
外核苷酸酶抑制剂及其使用方法
|
JP7203018B2
(ja)
|
2016-09-26 |
2023-01-12 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
クロモボックスタンパク質阻害剤およびその使用
|
LT3519050T
(lt)
|
2016-09-28 |
2023-08-25 |
Medicon Pharmaceuticals, Inc. |
Kompozicijos, skirtos oftalmologinių būklių gydymui
|
JP7030345B2
(ja)
|
2016-09-28 |
2022-03-07 |
メディコン ファーマシューティカルズ,インコーポレイテッド |
眼の状態を処置する組成物および方法
|
CN110352063A
(zh)
|
2016-11-08 |
2019-10-18 |
卡里塞拉生物科学股份公司 |
精氨酸酶抑制剂组合疗法
|
ES2970715T3
(es)
|
2016-12-22 |
2024-05-30 |
Prec Pharmaceuticals Inc |
Composiciones y métodos para inhibir la actividad de la arginasa
|
EP3510380B1
(en)
|
2016-12-23 |
2023-11-08 |
The Board of Trustees of the Leland Stanford Junior University |
Activity-based probe compounds, compositions, and methods of use
|
EP3570843A1
(en)
|
2017-01-18 |
2019-11-27 |
Vanderbilt University |
Fused heterocyclic compounds as selective bmp inhibitors
|
CN110325514B
(zh)
|
2017-02-24 |
2023-06-13 |
默克专利有限责任公司 |
作为二氢乳清酸加氧酶抑制剂的1,4,6-三取代的-2-烷基-1H-苯并[d]咪唑衍生物
|
KR102633530B1
(ko)
|
2017-03-31 |
2024-02-02 |
오리진 온콜로지 리미티드 |
혈액 장애를 치료하기 위한 화합물 및 조성물
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
US11325943B2
(en)
|
2017-06-02 |
2022-05-10 |
Stealth Biotherapeutics Inc. |
Crystalline salt forms of SBT-20
|
EP3655379B1
(en)
|
2017-07-19 |
2023-04-05 |
California Institute of Technology |
Methods for preparing bis-tetrahydroisoquinoline-containing compounds
|
KR20200068659A
(ko)
|
2017-10-11 |
2020-06-15 |
오리진 디스커버리 테크놀로지스 리미티드 |
3-치환된 1,2,4-옥사다이아졸의 결정질 형태
|
KR20200080254A
(ko)
|
2017-10-31 |
2020-07-06 |
쿠리스 인코퍼레이션 |
혈액학적 장애를 치료하기 위한 화합물 및 조성물
|
JP7378394B2
(ja)
|
2017-11-03 |
2023-11-13 |
オーリジーン オンコロジー リミテッド |
Tim-3およびpd-1経路の二重阻害剤
|
EP3706798A1
(en)
|
2017-11-06 |
2020-09-16 |
Aurigene Discovery Technologies Limited |
Conjoint therapies for immunomodulation
|
TW201938159A
(zh)
|
2017-12-22 |
2019-10-01 |
英商梅迪繆思有限公司 |
Keap1之btb域之小分子調節劑
|
US10745400B2
(en)
|
2018-03-14 |
2020-08-18 |
Vanderbuilt University |
Inhibition of BMP signaling, compounds, compositions and uses thereof
|
US10933084B2
(en)
|
2018-04-12 |
2021-03-02 |
MatRx Therapeutics Corporation |
Compositions and methods for treating elastic fiber breakdown
|
US11155638B2
(en)
|
2018-05-08 |
2021-10-26 |
Rhode Island Hospital |
Anti-CHI3L1 antibodies for the detection and/or treatment of nonalcoholic fattly liver disease/nonalcoholic steatonhepatitis and subsequent complications
|
WO2020006489A1
(en)
|
2018-06-29 |
2020-01-02 |
The Regents Of The University Of California |
New molecular tweezers against neurological disorders and viral infections
|
WO2020023917A1
(en)
|
2018-07-27 |
2020-01-30 |
California Institute Of Technology |
Cdk inhibitors and uses thereof
|
US20220218652A1
(en)
|
2018-09-05 |
2022-07-14 |
The General Hospital Corporation |
Methods of treating cytokine release syndrome
|
JP7504880B2
(ja)
|
2018-10-26 |
2024-06-24 |
ケロス セラピューティクス インコーポレイテッド |
Alk2阻害剤の結晶形
|
CN113574055A
(zh)
|
2019-01-18 |
2021-10-29 |
阿斯利康(瑞典)有限公司 |
Pcsk9抑制剂及其使用方法
|
MX2021008751A
(es)
|
2019-01-25 |
2021-11-12 |
Univ Brown |
Composiciones y metodos para tratar, prevenir o revertir la inflamacion y los trastornos asociados a la edad.
|
JP2022523510A
(ja)
|
2019-01-31 |
2022-04-25 |
エレクトロフィ,インコーポレイテッド |
粒子形成及び形態構造
|
AU2020234033B2
(en)
|
2019-03-14 |
2023-07-13 |
Astrazeneca Ab |
Lanabecestat for weight loss
|
EP3978076A4
(en)
|
2019-06-03 |
2023-02-22 |
Irimajiri Therapeutics Inc. |
CYCLIC AMIDE COMPOUNDS FOR THE TREATMENT OF RABIES AND METHOD THEREOF
|
CN110200947A
(zh)
*
|
2019-06-27 |
2019-09-06 |
深圳市泛谷药业股份有限公司 |
一种安非他酮肠溶缓释微丸胶囊及其制备方法
|
EP4027978A1
(en)
|
2019-09-13 |
2022-07-20 |
Elektrofi, Inc. |
Compositions and methods for the delivery of therapeutic biologics for treatment of disease
|
MX2022005810A
(es)
|
2019-11-12 |
2022-06-08 |
Genzyme Corp |
Heteroarilaminosulfonamidas de 6 miembros para tratar enfermedades y afecciones mediadas por la actividad de regulador de la conductancia transmembrana de la fibrosis quistica (cftr) deficiente.
|
WO2021113806A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
WO2021113809A1
(en)
|
2019-12-05 |
2021-06-10 |
Genzyme Corporation |
Arylamides and methods of use thereof
|
KR20210076875A
(ko)
|
2019-12-16 |
2021-06-24 |
주식회사 스마틴바이오 |
신생혈관형성인자의 억제를 위한 화합물 및 그 용도
|
WO2021158959A2
(en)
|
2020-02-07 |
2021-08-12 |
Elektrofi, Inc. |
Peptide particles and methods of formation
|
US20230065628A1
(en)
|
2020-02-19 |
2023-03-02 |
Elektrofi, Inc. |
Droplet Formation and Particle Morphology
|
CN115484934A
(zh)
|
2020-04-17 |
2022-12-16 |
伊勒卓菲公司 |
通过连续液滴形成和脱水形成颗粒的方法
|
WO2021263072A1
(en)
|
2020-06-25 |
2021-12-30 |
Dana-Farber Cancer Institute, Inc. |
Methods of treating disease
|
CA3191163A1
(en)
|
2020-08-10 |
2022-02-17 |
Dana-Farber Cancer Institute, Inc. |
Fused tricyclic pyrimidine-thieno-pyridine small molecule inhibitors of ubiquitin-specific protease 28
|
US20230271918A1
(en)
|
2020-08-10 |
2023-08-31 |
Dana-Farber Cancer Institute, Inc. |
Substituted 3-amino-4-methylbenzenesulfonamides as small molecule inhibitors of ubiquitin-specific protease 28
|
US20230265082A1
(en)
|
2020-08-10 |
2023-08-24 |
Dana-Farber Cancer Institute, Inc. |
Substituted 1,2,4-oxadiazoles as small molecule inhibitors of ubiquitin-specific protease 28
|
WO2022087433A1
(en)
|
2020-10-23 |
2022-04-28 |
Dana-Farber Cancer Institute, Inc. |
Covalent inhibitors of creatine kinase (ck) and uses thereof for treating and preventing cancer
|
EP4255433A4
(en)
|
2020-12-01 |
2024-05-29 |
Antecip Bioventures II LLC |
BUPROPION AND DEXTROMETHORPHAN FOR REDUCING THE RISK OF SUICIDE IN DEPRESSED PATIENTS
|
WO2022133237A2
(en)
|
2020-12-18 |
2022-06-23 |
Cornell University |
Methods of treating neurodegenerative disorders and stat3-linked cancers using suppressors of electron leak
|
JP2024504512A
(ja)
|
2020-12-21 |
2024-01-31 |
コーネル・ユニバーシティー |
ペプチド連結薬物送達系
|
US20240132480A1
(en)
|
2021-01-08 |
2024-04-25 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
TW202309022A
(zh)
|
2021-04-13 |
2023-03-01 |
美商努法倫特公司 |
用於治療具egfr突變之癌症之胺基取代雜環
|
WO2023034946A1
(en)
|
2021-09-03 |
2023-03-09 |
Genzyme Corporation |
Indole compounds and uses thereof in the treatement of cystic fibrosis
|
CA3230259A1
(en)
|
2021-09-03 |
2023-03-09 |
Junkai Liao |
Indole compounds and methods of use
|
WO2023056431A1
(en)
|
2021-10-01 |
2023-04-06 |
Nuvalent, Inc. |
Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds
|
TW202320768A
(zh)
|
2021-10-01 |
2023-06-01 |
美商努法倫特公司 |
雜芳族大環醚化合物之固體形式、醫藥組成物及製備
|
WO2023187422A1
(en)
|
2022-03-31 |
2023-10-05 |
Revolo Biotherapeutics Limited |
Compositions and their use in methods for treating intestinal inflammation
|
TW202400608A
(zh)
|
2022-04-07 |
2024-01-01 |
美商努法倫特公司 |
雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
|
WO2023196910A1
(en)
|
2022-04-07 |
2023-10-12 |
Nuvalent, Inc |
Methods of treating solid tumor using (19r)-5-chloro-3-ethyl-16-fluoro-10,19-dimethyl-20-oxa-3,4,10,11,23-pentaazapentacyclo[19.3.1.02,6.08,12.013,18]pentacosa-1(24),2(6),4,8,11,13,15,17,21(25),22-decaen-22-amine
|
WO2023212721A1
(en)
|
2022-04-29 |
2023-11-02 |
Elektrofi, Inc. |
Injectable suspensions
|
WO2023223015A1
(en)
|
2022-05-16 |
2023-11-23 |
Revolo Biotherapeutics Limited |
Methods and compositions for preventing or treating food allergies
|
WO2023250157A1
(en)
|
2022-06-24 |
2023-12-28 |
Cornell University |
Inhibitors of mycobacterium tuberculosis lipoamide dehydrogenase
|
WO2024006812A1
(en)
*
|
2022-06-30 |
2024-01-04 |
Axsome Therapeutics, Inc. |
Pharmaceutical compositions comprising bupropion and cysteine
|
WO2024006853A1
(en)
|
2022-06-30 |
2024-01-04 |
Antecip Bioventures Ii Llc |
Treatment of poor metabolizers of dextromethorphan with a combination of bupropion and dextromethorphan
|
US11717518B1
(en)
|
2022-06-30 |
2023-08-08 |
Antecip Bioventures Ii Llc |
Bupropion dosage forms with reduced food and alcohol dosing effects
|
US11844797B1
(en)
|
2023-04-20 |
2023-12-19 |
Antecip Bioventures Ii Llc |
Combination of dextromethorphan and bupropion for treating depression
|
US11730706B1
(en)
|
2022-07-07 |
2023-08-22 |
Antecip Bioventures Ii Llc |
Treatment of depression in certain patient populations
|
WO2024013209A1
(en)
|
2022-07-13 |
2024-01-18 |
Astrazeneca Ab |
Pcsk9 inhibitors and methods of use thereof
|
WO2024036097A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds and isotopologues thereof
|
WO2024036098A1
(en)
|
2022-08-12 |
2024-02-15 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether compounds
|
WO2024086634A1
(en)
|
2022-10-19 |
2024-04-25 |
Nuvalent, Inc. |
Heteroaromatic macrocyclic ether chemotherapeutic agents
|